Shares of Geron Corporation (NASDAQ:GERN – Get Free Report) traded up 16.4% during mid-day trading on Wednesday . More Geron NewsHere are the key news stories impacting Geron this week:Get Geron alerts:Positive Sentiment: Geron reported second-quarter revenue of $57.48 million , exceeding analysts’ $55.30 million estimate, as sales of its Rytelo treatment reached a record level. Geron Stock PerformanceThe company has a quick ratio of 4.96, a current ratio of 6.78 and a debt-to-equity ratio of 0.52. Finally, 55 North Private Wealth LLC bought a new position in shares of Geron in the fourth quarter worth $29,000. Geron Company Profile(Get Free Report)Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality.